SLC5A2 and type 2 diabetes mellitus: The SURPASS-4 (Eli Lilly and Company, 2022a) (NCT03730662) trial compared the safety and efficacy of three tirzepatide dosages (5 mg, 10 mg, and 15 mg) with titrated insulin glargine (metformin, sulfonylurea, or SGLT-2 inhibitor) in more than 2,000 adults with T2DM who have an elevated CVD risk.